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Osteogenesis imperfecta (OI) is a heterogeneous genetic 
disorder that affects bone and other connective tissue 
(Sillence et al., 1979a; Sillence et al., 1979b; Prockop and 
Kivirikko, 1984a) . It is characterized by fragility of 
bones, blue sclerae, thin skin, joint hypermobility, hearing 
impairment and dentinogenesis imperfecta (Sillence 1988; 
Byers 1989; Kuivaniemi et al., 1991). All of the affected 
tissues are rich in type I collagen (Byers 1990; Sillence 
1988; Kuhn 1987). Molecular defects in the structure and 
synthesis of Type I collagen have been found in many 
individuals with the OI phenotype (Prockop et al., 1989; 
Prockop et al., 1994). 
Severity of the OI symptoms varies greatly between 
individuals and very rarely have two cases been found with 
exactly the same molecular defect (Pope et al., 1985; Rose et 
al., 1994). There are reports of many cases where 
asymptomatic individuals carry the same Type I collagen 
defect as those family members with the OI phenotype 
(Superti-Furga et al., 1989; Cohn and Byers, 1991; Sykes et 
al., 1990). There have even been cases of the progressively-
deforming, moderately severe form of the disease (Type III) 
2 
that show no apparent Type I collagen defects (Byers et al., 
1988b; Wenstrup et al., 1990). Thus additional genes must 
contribute to the OI phenotype other than the Type I collagen 
genes. 
Previous studies have shown the existence of two 
undescribed collagen-like loci that are different from other 
already-characterized collagen genes (Cammarata et al., 1991; 
Doering et al., 1993; Cammarata, 1994). Site 1 is detected 
as a 7.4kb Hind III restriction fragment which contains a 
3. Okb Pst I fragment in normal individuals. Site 2 is 
detected as a 4.6kb Hind III fragment that overlaps with a 
5.2kb Pst I fragment in normal individuals. This site has 
recently been cloned and localized to chromosome 17 (Doering 
et al., 1993; Cammarata, 1994). Deletions at the two sites 
occur more frequently in OI Type III patients than the 
normal population (Cammarata et al., 
1987). At both of the new sites 
1991; Doering et al., 
the deletions are of 
heterogeneous size and occur spontaneously (Doering et al., 
1987). This data for OI patients, when compared to that for 
normal individuals demonstrates that the frequent occurrence 
of deletions at these loci is associated with Type III OI. 
The new loci may code for a component(s) of connective tissue 
that can contribute to the OI phenotype if defective, or may 
interact with Type I collagen defects to produce the OI 
phenotype. 
3 
Tandemly-repeated sequences have been shown to be 
responsible for disorders such as fragile X syndrome and 
myotonic dystrophy, where length polymorphisms occur as a 
result of variable numbers of copies of repeats (Caskey et 
al., 1992). Also, a locus containing uncharacterized 
collagen-like sequences has been shown to have substantial 
length polymorphism arising from variable numbers of tandem 
repeats (Brookes et al., 1989). These studies suggest that 
tandemly repeated sequences are inherently unstable and prone 
to further deletion. Variability in the number of copies of 
the repetitive sequence are what cause such heterogeneity 
among individuals. 
The purpose of this study was to localize and determine 
the molecular organization of the deletion site at Site 2. 
Specifically I wished to determine whether tandemly 
repetitive sequences are responsible for this deletion. 
Restriction enzymes with sites in the locus were used to 
digest patient and normal DNAs in order to localize the 
deletion site. Comparison of the fragment sizes obtained 
from the normal to those from the patient DNA delineated this 
localization. The regions surrounding the deletion site in 
the clone were then sequenced to determine their 
characteristics. Sequences adjacent to the deletion site 
that were non-repetitive and non-complementary were used to 
construct DNA primers for PCR reactions. The polymerase 
chain reaction was utilized to amplify the patient DNA to 
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allow sequencing of these regions. The products of the PCR 
reaction were electrophoresed on agarose gels, and since 
heterozygotes were used, two different-sized allele fragments 
were separated from each other and purified by band-stab PCR 
directly from the gel. The PCR-amplified Site 2 fragment was 
then directly sequenced using Cycle-Sequencing methods. The 
characterization of the deletion in the patient was perf armed 
by comparing the sequence of this allele to that of the 
normal allele. This identified deletion endpoints, and 
indicates that tandemly repetitive sequences are involved in 
the mechanism causing the deletions. 
CHAPTER II 
REVIEW OF RELATED LITERATURE 
OI and Type I Collagen 
Osteogenesis imperfecta (OI) is a heritable 
connective-tissue disorder in which bone fragility is the 
main clinical manifestation (Cole et al., 1989; Byers 1989; 
Bateman et al., 1991). It is one of the most common 
connective tissue disorders and occurs with a frequency of 
approximately 1 in 5,000 to 10,000 individuals (Byers and 
Steiner, 1992). The severity of the symptoms vary and 
patients may also exhibit blue sclerae, hearing loss, thin 
skin, joint hypermobility and dentinogenesis imperfecta 
(Sillence, 1988; Byers, 1989). Since all the tissues 
affected by OI are rich in Type I collagen (Kuhn, 1987; 
Sillence, 1988; Byers, 1989), most studies of the disease 
have focused on the structure of this protein. Many cases 
of OI have been shown to involve alterations in the 
structure and/or synthesis of Type I collagen, but only 
rarely are two cases found with exactly the same defect 
(Rose, 1994) . The phenotype is caused by mutations in 
either of the genes encoding the al or a2 chains of Type I 
5 
collagen, COLlAl or COL1A2 (Rose et al., 1994; Forlino et 
al., 1994). 
Type I collagen is the major protein of mature bone, 
skin, tendons and ligaments (Kuhn, 1987; Sillence, 1988) 
Collagens are extracellular proteins composed of three 
helical polypeptide chains that associate with one another 
to form a right-handed triple helical structure (Prockop 
and Kivirikko, 1984a) . Type I collagen is a heterotrimer 
composed of two al chains and one a2 chain. Both types of 
chains are synthesized as procollagen molecules consisting 
of a triple helical segment flanked by amino and carboxy 
terminal propeptides. The triple helical domain is 
characterized by a regular Gly-X-Y repeating unit, where X 
is often praline and Y is often hydroxyproline, although 
they can be any amino acid except cysteine, tyrosine or 
tryptophan (Kuhn, 1987) . 
Collagen Formation 
Helix formation begins at the carboxy end of the 
chains and proceeds in a zipper-like fashion toward the 
amino terminus. The glycine residue in every third 
position facilitates the folding of the three chains into 
the triple helical conformation, which allows tight 
6 
association of the polypeptide chains. During the helix 
assembly in the rough endoplasmic reticulum, praline and 
lysine residues are hydroxylated and some prolyl residues 
are further glycosylated. These post-translational 
modifications continue until the completion of helix 
formation (Byers, 1989; Prockop, 1984b), so the extent of 
modification depends on the rate of helix formation 
7 
(Bateman et al., 1988). Propeptides are enzymatically 
removed by proteases after secretion from the cell into the 
extracellular matrix (ECM) . This allows the molecules to 
spontaneously align into mature collagen fibrils which are 
stabilized by covalent lysyl-derived crosslinks (Bornstein 
and Sage, 1980; Kuhn, 1987). The molecular crosslinking 
also occurs in the mature molecule via disulfide bonding 
between cysteine residues. 
A compact, rigid triple helix is essential for tensile 
strength in mature collagen fibers (Byers, 1989). Collagen 
polypeptides are arranged in parallel stacks, and 
crosslinked to form staggered microfibrils (Prockop, 1984) 
Because post-translational modification is dependent on 
the rate of helix formation, mutations in the Type I 
collagen genes that result in a decrease in the rate of 
triple helix formation often result in overmodification 
(Bateman et al., 1986; Bonadio and Byers, 1985). Post-
translational modification and intermolecular crosslinking 
are both important in stabilizing the molecular arrangement 
8 
within collagen molecules and between fibrils (Kuivaniemi 
et al., 1991). In bone, collagen fibrils are densely 
packed. If a defective molecule is incorporated into the 
uniform fibril environment, the strength of the tissue will 
be compromised. It causes not only instability in that 
molecule, but all the adjacent molecules are affected. It 
would be less detrimental to produce fewer normal collagen 
chains than to produce and incorporate a large number of 
defective ones. 
Type I Collagen Defects in OI 
As a result of biochemical, molecular genetic, and 
linkage studies, there is now little question that the vast 
majority of patients with OI are heterozygous for mutations 
in Type I procollagen (Sykes et al., 1990; Byers et al., 
1988c; Wenstrup et al., 1990). More than 70 different 
mutations in the two genes that encode the chains of Type I 
collagen, the major protein of bone, have been identified 
as the molecular cause of different forms of OI (Byers et 
al., 1991). The mildest forms of OI generally result from 
overall production of Type I procollagen being synthesized 
being decreased due to reduced synthesis of the pro al(I) 
chain (Bateman et al., 1988). These defects may be due to 
non-functional COLlAl alleles or ones that produce unstable 
products (Willing et al., 1992). Mutations in Type I 
collagen genes which result in decreased rates of triple 
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helix formation, cause overmodif ication of the protein 
chains (Bonadio and Byers, 1985) which interferes with the 
folding, processing and formation of stable collagen 
molecules. These unstable molecules are often rapidly 
degraded and result in reduced amounts of collagen (Barsh 
and Byers, 1981). There are a number of cases that have 
overmodif ied chains due to mutations in the sequence of the 
triple helical domain (Bateman et al., 1988; Deak et al., 
1991; de Vries et al., 1986). The mutations include point 
mutations, insertions, deletions and re-arrangements in the 
COLlAl gene that codes for the pro-al(I) chain and in the 
COL1A2 gene that codes for the pro-a2(I) chain of Type I 
collagen (Byers, 1990; Bateman et al., 1991). 
The most commonly studied gene defects in OI are point 
mutations which cause a substitution for a Gly residue in 
the triple helix (Wallis et al., 1990; Cole et al., 1992). 
These substitutions can also cause splicing defects which 
can result in missing coding information (Kuivaniemi et 
al., 1988). Deletions can also cause splicing defects 
(Tromp and Prockop, 1988) . Occasionally insertions have 
been observed that are responsible for frameshift mutations 
(Willing et al., 1990; Genovese at al., 1989). While the 
detailed nature of the structural defects in the collagen 
protein have been characterized in an increasing number of 
OI cases, only occasionally have two cases been found to 
have exactly the same biochemical defect (Rose et al., 
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1994; Prockop et al., 1994). 
OI Types 
Osteogenesis imperfecta is classified into four 
different types based on clinical symptoms and the mode of 
inheritance (Sillence et al., 1979b; Byers et al., 1987; 
Prockop and Kivirikko, 1984a) . OI Type I is a mild 
dominantly inherited form (Sillence et al., 1979a; Byers et 
al., 1988c; Prockop, 1984b) that involves defects in the 
structure or synthesis of Type I collagen. The clinical 
features associated with Type I OI are bone fragility which 
is reduced at puberty, blue sclerae, deafness and short 
stature (Sillence, 1988) . The triple helix in Type I cases 
of OI are as stable as normal collagen or only moderately 
unstable, and in some cases the helix stability is 
explained by Type I mutations occurring in the X or Y 
position of the Gly-X-Y sequence rather than in the glycine 
position as occurs in Type II OI (Steinmann et al., 1986). 
This may account for the milder phenotype (Bateman et al., 
1988a) . There have been Type I OI patients found with 
mutations that cause splicing defects with exon skipping in 
the helical domain of the COLlAl gene. The mild phenotype 
may be a result of the deleted molecules not being 
incorporated into the matrix (Superti-Furga et al., 1993; 
Mattes et al. 1994). In many OI Type I cases, even when no 
structural defects have been identified, the total amount 
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of Type I procollagen synthesized is low, due mainly to 
reduced synthesis of the pro-al(I) chain (Byers et al., 
1988c; Bateman et al., 1988b). Presence of non-functional 
COLlAl alleles may be the cause of these defects (Willing 
et al., 1992; Rowe et al., 1985). By analysis of 
restriction length polymorphisms (RFLPs), the phenotype has 
been shown to consistently segregate with one or the other 
Type I collagen genes (COLlAl or COL1A2) (Tsipouras et al., 
1984; Falk et al., 1986; Sykes et al., 1990). These 
results clearly show that the defects in the structural 
genes for Type I procollagen are responsible for this form 
of OI. 
OI Type II is the severe perinatal form that has been 
well studied. Its clinical characteristics include 
neonatal dwarfism, severe bone deformity as a result of 
multiple fractures and death in utero or shortly after 
birth (Sillence, 1988) . Most cases are the result of new 
dominant mutations in the Type I collagen structural genes 
which affect helix formation (Byers et al., 1988a; Byers et 
al., 1988b). Mutations have been found in both the COLlAl 
and COL1A2 genes which results in substitutions for one of 
the glycines of the triple helix. The new substituted 
residue is often cysteine or arginine (Vogel et al., 1987; 
Bateman et al., 1988b) but valine (Patterson et al., 1989), 
serine (Lamande et al., 1989) and aspartate (Baldwin et 
al., 1989) substitutions have also been seen. The 
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substitutions are found at a number of positions throughout 
the chains (Lamande et al., 1989; Baldwin et al., 1989; 
Bateman et al., 1988b). These results indicate that 
mutations associated with the Type II phenotype are not 
located in only particular positions of the helix. 
Many cases appear to be point mutations that cause a 
disruption in the regular Gly-X-Y sequence in the triple-
helical domain which leads to an unstable helix that is 
slow in forming and results in poor secretion of the 
unstable procollagen molecule into the extracellular matrix 
(Willing et al., 1988; Cohn et al., 1988b). Since 
modification of collagen chains occurs until a stable 
triple helix is formed, Type I collagen chains usually 
contain excess post-translational modification as a result 
of the slowly forming helices in these cases (Byers et al., 
1988; Byers et al., 1988; Bonadio and Byers, 1985). Other 
mutations such as genomic deletions or point mutations in 
the helical portion of COLlAl (Barsh et al., 1985; Chu et 
al., 1985; Hawkins et al., 1991) or COL1A2 (Willing et al., 
1988) can lead to splicing defects and missing exons (Tromp 
and Prockop, 1988) . 
OI Type III is the progressively-deforming, moderately 
severe form of OI. It is deemed progressive in nature due 
to repeated multiple fractures that result in severe 
deformity of the limbs and spine. Even though it is one of 
the most common types, it is the least characterized 
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(Sillence, 1988). A few autosomal recessive cases exist, 
yet most are due to spontaneously-occurring dominant 
mutations (Thompson et al., 1988). RFLP analysis of 
several recessive pedigrees for Type III OI have shown that 
this form is unlinked to either of the Type I collagen 
genes (Byers et al., 1987; Aitchison et al., 1988). A few 
reports exist of substitutions and deletions in the Type I 
collagen genes of OI Type III patients (Pihlajaniemi et 
al., 1984; Byers et al., 1983a; Pack et al., 1989). There 
are also many cases where no such defects have been found 
(Byers et al., 1988a; Beighton et al., 1988; Wenstrup et 
al., 1990). For these cases where no Type I collagen 
mutation is present, defects in genes encoding bone-
specific proteins or other ECM components could be 
responsible for expression of the OI phenotype (Byers, 
1990). 
OI Type IV is the more severe dominantly inherited 
form that also involves a variety of Type I collagen 
defects (Sillence, 1988) . Its clinical severity is 
moderate, with patients having pale blue or white sclerae 
and variable deformity of the long bones (Sillence, 1988) . 
Amino acid substitutions at glycine positions in the triple 
helical region of the a2(I) chain appear to be the basis 
for many Type IV cases (Byers et al., 1988c; Wenstrup et 
al., 1988). RFLP analysis has shown that in many cases 
this form of the disease segregates with the COL1A2 gene 
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(Superti-Furga et al., 1989; Sykes et al., 1990). The 
kinds of defects found in Type IV are similar to those seen 
in Type II OI. This shows that the different forms of OI 
cannot be distinguished by the collagen chain in which the 
mutation occurs or even by the position of the mutation in 
the chain. 
It has not been possible to correlate specific defects 
with particular OI phenotypes because there is still little 
understanding of how defects in Type I collagen structure 
cause the various types of OI. Despite the large number of 
studies of OI cases at the molecular level, the different 
forms of the disease cannot be distinguished by which of 
the two Type I collagen chains contains the mutation. Even 
when mutations map very closely to each other in the same 
chain, they can be associated with OI phenotypes of widely 
varying severity (Cohn and Byers, 1991). There is very 
little understanding of the functional domains of the 
collagen molecule, which may add to the confusion in 
determining correlations between defect and phenotype 
(Sykes et al., 1990). There are many cases where members 
of a family carry the same Type I collagen defect and show 
a wide variation of severity, even being asymptomatic 
(Sykes et al. 1990; Superti-Furga et al., 1989). Thus, the 
variation in symptoms may involve other collagen types or 
matrix proteins that interact with the various domains of 
Type I collagen and thus affect the phenotype. 
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Collagen Types 
At least seventeen kinds of collagen besides Type I 
have been identified, but little is known about how they 
contribute to the structural integrity of the extracellular 
matrix (Mayne and Burgeson, 1987; Sandell and Boyd, 1990; 
Shaw and Olsen, 1991; van der Mark et al., 1992). They can 
be classified into three main groups depending on their 
structure. 
Group one consists of the f ibrillar collagens (Types 
I, II, III, V, and XI). All members of the group have 
similar structural features of being homo or heterotrimers. 
They all contain three polypeptide chains, with a monomer 
size greater than 95 kiloDaltons, and long uninterrupted 
triple-helical domains containing the characteristic Gly-X-
Y repeating amino acid sequence. Most of the exons in the 
helical coding regions of these genes are 54bp or multiples 
of 54, and all of the exons in the helical coding regions 
are multiples of 9bp in length, corresponding to integral 
numbers of the basic Gly-X-Y repeat, beginning with the 
codon for glycine and ending with a triplet preceding a 
glycine codon (Sandell and Boyd, 1990; de Wet et al., 1987; 
van der Mark et al., 1992). The genes for these collagens 
share a highly conserved exon-intron organization. The 
coding sequences are divided into nearly identical numbers 
of exons, and all intrans regardless of size, are located 
in homologous positions in each gene (Sandell and Boyd, 
16 
1990; Fleischmajer et al., 1990). 
Type III collagen is often present in minor amounts in 
the same fibrils with Type I. Small amounts of Type V 
collagen are also associated with Type I fibrils and 
occasionally with Type II fibrils (Mayne and Burgeson, 
1987). Type v and XI are more similar to each other 
structurally than any other two collagens (Greenspan et 
al., 1991). Type XI is expressed in all cartilage tissue 
and may be associated as a minor component with the Type II 
fibrils that make up those tissues (Mayne and Burgeson, 
1987). 
Group two consists of the large nonfibrillar Types IV, 
VI and VII. They all have monomer chain sizes of greater 
than 95 kiloDaltons with large globular domains, and a 
number of interruptions in the repeating Gly-X-Y repeat 
within the triple helical domains (Mayne and Burgeson, 
1987; Sandell and Boyd, 1990; Parente et al., 1991). These 
interruptions allow the molecules flexibility which is not 
possible in the fibrillar collagens (Hoffman et al., 1984). 
Types IV and VI are heterotrimers, while Type VII is 
believed to be a homotrimer (Fleischmajer et al., 1990). 
This group is not well characterized; only the genes for 
the two chains of Type IV and three chains of Type VI have 
been studied in detail. Their exon sizes and overall 
intron-exon patterns are completely different from the 54bp 
exon pattern of the fibrillar collagens (Soininen et al., 
1988; Soininen et al., 1989). These collagens aggregate 
through end-to-end associations of monomer units rather 
than by lateral association (Timpl et al., 1981). 
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The function of Type IV collagen in the matrix is not 
understood. It is found in basement membranes and 
interacts weakly with cell membranes, laminin and 
proteoglycans. Type VI collagen may serve as a link 
between other matrix components and cells, yet does not 
appear to be physically associated with the major fibrillar 
elements in extracellular matrices. Type VII seems to link 
the basal surface of epithelial cells with the dermis as 
part of the anchoring fibrils, but the biochemical basis 
for this is unclear (Mayne and Burgeson, 1987; Fleischmajer 
et al., 1990). 
Group three consists of the short-chain Types VIII, 
IX, X, XII, XIV and XVI. These collagens all have monomer 
chains of less than 95 kiloDaltons with many interruptions 
in the Gly-X-Y repeat of their triple helical domains 
(Sandell and Boyd, 1990) . This collagen group shows great 
variation in gene structure. Two chains of Type VIII and 
one of Type X have been characterized, and they show common 
structural features, that consist of 8 interruptions of the 
helix with similar sequence, length and relative location 
(Yamaguchi et al., 1989; Muragaki et al., 1991). Both 
Types IX and X contain short collagenous domains, yet the 
5kb gene for pro-al(X) collagen contains only 3 exons and 
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no intrans in its triple helical coding sequences (Sandell 
and Boyd, 1990). The genes for pro-al(IX) and pro-a2(IX) 
have been partially characterized and only a few 54bp exons 
have been found in either of them (Sandell and Boyd, 1990; 
Ninomiya et al., 1990). Type VIII collagen is found in 
basement membrane of corneal endothelial cells and Type X 
in the endochondral ossification zones of cartilage 
(Muragaki et al., 1991; Reichenberger et al., 1992). 
Types IX, XII, XIV and XVI have been grouped into a 
subgroup called FACIT collagens (fibril-associated 
collagens with interrupted triple helices) to emphasize 
their homologous structures and possible function (Shaw and 
Olsen, 1991) . The molecules in this class contain more 
than one triple-helical domain separated by non-triple-
helical segments (Shaw and Olsen, 1991) . The FACIT 
proteins are associated with fibrils composed of f ibrillar 
collagens. FACITs all share structural features, yet their 
sizes and primary structures vary greatly (Pan et al., 
1992) . They may be important in the organization and 
stability of extracellular matrices. 
Type IX collagen is found in cartilage and is arranged 
in a periodic fashion along the surface of the major 
fibrils made up of Types II and XI (Shaw and Olsen, 1991) . 
The globular domain of Type IX projects out of the surface 
of the major fibril possibly facilitating interactions 
between the major fibril and other molecules of the matrix 
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(Shaw and Olsen, 1991). Type XII, with a structure 
homologous to that of Type IX, is found primarily in 
tissues where Type I is the major fibrillar collagen. 
Although Type XII co-localizes with Type I in many tissues, 
it is not found in skin or bone (Shaw and Olsen, 1991) . 
Another recently discovered collagen, Type XIV, is found in 
skin and, since it is homologous to Types IX and XII it may 
interact with the major fibrils composed of Types I and V 
(Shaw and Olsen, 1991; Dublet and van der Rest, 1991). 
Both types XII and XIV localize near the surface of banded 
collagen fibrils and influence interaction between adjacent 
fibrils as-well-as participate in extracellular matrix 
deformability (Nishiyama et al., 1994). Type XVI collagen 
is made by fibroblasts and keratinocytes (Pan et al., 
1992). It has structural similarities to Types IX and XII 
(Pan et al., 1992). 
New collagen loci continue to be discovered and 
characterized. The newly identified Type XIII gene has a 
helical-coding domain made up of several 54bp exons and a 
number of other exons with unrelated sizes (Tikka et al., 
1991) . This gene has both fibrillar and non-fibrillar gene 
characteristics. The collagen structure it codes for 
resembles that of the FACIT collagens. More new collagen 
types include XV, XVII and XVIII that are characterized by 
many short triple helical domains, unlike the long, 
contiguous domains found in the other collagen types. Type 
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xv is found in kidney and pancreas and Type XVII is found 
in hemidesmosomes, yet the function of these collagens is 
still unknown (Muragaki et al., 1994). BPAG2 is yet 
another new collagen and is found in stratified squamous 
epithelia. It contains both collagenous and non 
collagenous domains. Its exon organization is different 
from any other f ibrillar or nonf ibrillar collagen genes (Li 
et al., 1991). 
Newly-Identified Collagen-Like Loci 
Recent studies have identified two undescribed 
collagen-like loci that are different from other already 
characterized collagen genes (Doering et al., 1993). The 
loci were detected with a pro-a2(I) cDNA probe (Doering et 
al., 1993). The normal restriction fragments containing 
Site 1 are a 7.4kb Hind III that contains a 3.0kb Pst I 
fragment. Site 2 is detected in normal individuals as a 
4.6kb Hind III fragment that overlaps a 5.2kb Pst I 
fragment and is localized to chromosome 17 (Doering et al., 
1993). This site has been cloned from a chromosome 17-
specific lambda phage library and a restriction map has 
been constructed (Cammarata et al., 1991). The 4.6kb 
HindIII fragment was isolated and the triple helical coding 
region within it was characterized by restriction mapping 
and sequencing (Cammarata, 1994) . Determining the detailed 
molecular organization of this locus is the inital step 
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necessary to characterize the structure, and function, of 
the putative protein that is coded for by the new locus. 
Recent studies of the new collagen-like loci suggest 
that deletion sites could be contributing to the OI 
phenotype. Deletions that are heterogeneous in size and 
occur in a spontaneous fashion have been detected at these 
sites in genomic DNA of Type III OI patients (Breslin et 
al., 1995; Cammarata et al., 1991; Doering et al., 1987). 
While these deletions do occur in normal individuals they 
are much less frequent there and less heterogeneous in size 
(Doering et al., 1990; Cammarata et al., 1993). Because of 
a very low frequency of heterozygote deletions at Site 2, 
the alleles there are not in Hardy-Weinberg equilibrium. 
This is important because it suggests that Site 2 is at a 
locus that is expressed and that its genotype may result in 
a disadvantageous phenotype that selection will operate 
against. The new loci may code for a connective tissue 
component(s) which, when defective, contributes to the OI 
phenotype (Doering et al., 1993). It is suggested that the 
disease phenotype requires an interaction between Type I 
collagen and the products of other loci, as suggested by 
the many examples of asymptomatic individuals carrying the 
same Type I collagen as their family members who have OI 
(Cohn and Byers, 1991; Constantinou et al., 1989; Hollister 
et al., 1988). The deleted alleles at Site 2 may not cause 
the disease directly, but the defective product of the 
locus may interact with other mutant connective tissue 
components to produce the OI phenotype. The deletions in 
patients then may act independently or by modulating the 
effect of Type I collagen defects. 
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Length polymorphisms where insertions/deletions change 
the length of DNA loci have been shown to be caused by 
various kinds of repetitive sequences (Sykes et al., 1985; 
Lee et al., 1991; Sykes et al., 1990). Tandemly-repeated 
sequences normally cause the length polymorphisms (Caskey 
et al., 1992). Direct repeats have also been shown to be 
involved in causing deletions within collagen genes (Chu et 
al., 1985; Sykes et al., 1985; Hawkins et al., 1991). 
Fascioscapulo-humeral muscular dystrophy (FSHD) has 
recently been shown to be associated with deletions in a 
tandemly repeated sequence (van Deutekom et al., 1993; 
Winokur et al., 1994). In fragile X syndrome, myotonic 
dystrophy and Huntington's disease, variable numbers of 
tandemly-repeated sequence cause longer polymorphisms in 
the alleles of affected individuals. There is also a range 
of premutation alleles in a range between that of normal 
and affected individuals seen in individuals with these 
diseases (Caskey et al., 1992; Sutherland and Richards, 
1995) . These alleles may cause mild or no disease symptoms 
in the individual carrying them, but long alleles arise 
spontaneously in their affected children (Caskey et al., 
1992). The parental deletions we have observed in OI 
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families may give rise to further spontaneous deletions in 
their children, which then could contribute to the OI 
phenotype. The mechanism responsible for the instability 
and frequent deletions at Site 2 may be similar to that of 
these other diseases that are associated with unstable 
tandem repeats. 
By determining the molecular organization of deletions 
at Site 2 in OI patients it may be possible to determine 
the mechanism responsible for the frequent deletions. The 
deletion location in Site 2 was determined and then 
sequenced in deleted and undeleted alleles to define 
deletion sizes, endpoints and the involvement of tandemly 
repeated sequences. These studies will ultimately provide 
understanding as to how the abnormalities caused by the 
deletions contribute to the OI phenotype. 
CHAPTER III 
MATERIALS AND METHODS 
Experimental Approach 
The purpose of this study was to localize and 
determine the molecular organization of the deletion site 
in one of the new collagen-like loci (Site 2). To 
characterize the deletions in the Site 2 locus (4.6kb 
HindIII fragment), the location of the deletion was 
determined. The Site 2 clone was used to probe blots of 
restriction digested normal and patient DNAs, to 
approximately localize the deletions within the 4.6kb site. 
Sequencing of the cloned normal locus in the region where 
deletions occur was done to determine the nature of the 
sequence. Primers for PCR reactions were then chosen from 
non-repetitive, non-complementary sequences in this region. 
PCR was then done on patient DNAs to isolate the deletion 
region and to allow its sequencing. The molecular nature 
of the deletions was then determined by comparing the 
sequence of a short allele in an OI patient to the normal 
allele. This was done in order to determine the deletion 




Restriction Enzyme Digests 
To localize the deletion site within the locus, DNA 
was restriction enzyme digested by established methods 
using single and double enzyme combinations (Doering, 1977; 
Peterson et al., 1980; Rosenthal et al., 1984). 
Restriction enzymes with sites in the 4.6kb (Site 2) clone 
were used to digest DNAs from a normal individual and from 
a patient with a homozygous 200bp deletion at Site 2. A 
comparison of the fragment sizes obtained in the control to 
that of the patient was done to localize the deletion. The 
smallest region where the fragment sizes are different 
between the normal and patient allowed this localization. 
All restriction enzymes were purchased from Bethesda 
Research Laboratories (Bethesda, MD) and used in the 
supplier's recommended buffers. Restriction digests were 
stopped by adding 0.5% SDS and lOmM EDTA. Gel 
electrophoresis was carried out on 0.9% agarose gels 
(Rosenthal and Doering, 1983) and the DNA transferred to a 
nylon membrane (Gene Screen Plus hybridization membranes; 
NEN Research Products, Boston, MA) using the alkaline 
transfer method (Reed and Mann, 1985) . The DNA size 
markers used were lambda phage DNA digested with HindIII 
and ¢-X 174 phage DNA digested with HaeIII. 
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Nick Translation and Hybridizations 
The method for locating the deletion involved using 
the Site 2 radiolabeled clone as a probe to compare 
restriction fragment sizes obtained in a normal control to 
that in a patient with the deletion. The EcoRI/SstI 
fragment of the Site 2 clone P4.6 (Cammarata, 1994), which 
contains no repetitive sequences was 32 P-labeled by nick 
translation (Rigby et al., 1977). Prehybridization of the 
membrane was carried out for at least 5 hours at 37°C with 
agitation (Doering et al., 1982; Rosenthal and Doering, 
1983) in 40ml of hybridization solution (50% formamide, 
0.9M NaCl, 50mM Tris pH 7.5, 1% sodium dodecyl sulfate, 
lOµg/ml denatured E. coli DNA). Denatured nick translated 
probe (6ng/ml) was added to the prehybridized membranes and 
incubation proceeded at 37°C for a minimum of 16 hours with 
agitation. Membranes were washed twice at room temperature 
for 30 minutes in 2X SSC (lX SSC is 150mM NaCl, 15mM sodium 
citrate, 0.1 mM EDTA); twice at 60°C for 30 minutes in 2X 
SSC with 1% SDS; and lastly, twice at room temperature for 
30 minutes in 0.5X SSC. Autoradiography was then done 
using Kodak XAR x-ray film and Dupont Lightning-Plus 
intensifying screens as necessary. 
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DNA Sequencing 
To determine the sequence in the deletion site, DNA 
sequencing of the Site 2 subclone P4.6ME (Cammarata, 1994) 
was done by the dideoxy method (Sanger et al., 1977) using 
the "AmpliTaq" kit (Perkin Elmer Cetus, Norwalk, CT). The 
double-stranded template and primer were denatured and 
reannealed as follows prior to extension/termination 
reactions. Three micrograms of template DNA and O.Spmol 
primer DNA were combined in a total volume of 20.0µl. NaOH 
and EDTA were added to a final concentration of 0.2M and 
0.2rnM respectively, and the mixture was incubated for 5 
minutes at 85°C. The tube was placed on ice, and 6.0µ1 of 
3M NaOAC, pH 5.2 and 60µ1 100% EtOH were added to 
precipitate the denatured DNA. This solution was placed at 
-20°c for 20 minutes. The DNA was pelleted by 
centrifugation at 9,500rpm in an SHMT rotor (Sorvall/E.I. 
duPont, Newtown, CT) for 20 minutes and washed carefully 
with 70% EtOH. The dried DNA pellet was resuspended in 
14ul distilled H2 0 and reannealed for 5 minutes at 37°C 
followed by 7 minutes at room temperature. 
The extension and termination reactions were carried 
out according to the manufacturer's instructions for 
sequencing double stranded DNA using the "Amplitaq" 
sequencing kit (Perkin Elmer Cetus, Norwalk, CT). The DNA 
was tagged by adding 35S-labelled dATP nucleotides during 
the extension reaction. The T7 primer was used and 
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extension began from the Eco RI site, or in the case of the 
nested deletion clones, sequences adjacent to this site, 
and proceeded to the left through the helical coding 
region. 
The sequence that was determined was highly repetitive 
and internal primers would not allow reading far enough 
into the sequence. Subclone deletions of the DNA fragment 
of interest were generated in order to facilitate reading 
far enough into the sequence to locate the deletion region. 
Generation of Nested Deletions 
Nested deletions were generated using the "Erase-a-
Base" system (Promega Corporation, Madison, WI) according 
to the manufacturer's instructions. In order to sequence 
the region where the deletions occur, the Site 2 subclone, 
P4.6ME, was cloned into a pGEM7Zf+ vector (Promega Biotech, 
Madison, WI), and digested by exonuclease III digestion 
from the Eco RI site, with samples being removed at timed 
intervals. Sl nuclease treatment was done to remove single 
stranded tails left from digestion. The Sl nuclease was 
neutralized and heat inactivated, and Klenow DNA polymerase 
was added to generate blunt ends which were ligated to 
circularize the plasmids for transforming competent cells 
(Sambrook et al., 1989). The deleted subclones were 
screened by doing plasmid mini-preps (Mierendorf et al., 
1978) to determine subclones of the appropriate size (see 
Figure 3). Overlapping subclones at intervals that were 
far enough into the region were sequenced (P4.6ME-9, 
P4.6ME-13, P4.6ME-18). Sequence analysis was done with 
standard computer programs (Vasios et al., 1987). 
Sequences in the region of the deletion site allowed the 
construction of DNA primers for PCR reactions. The 
sequences necessary for primers are non-repetitive, non-
complementary sequences of approximately 20-25bp long 
(Innis et al, 1990). 
Polymerase Chain Reaction 
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Sequence analysis of the P4.6ME subclone sequences was 
done with the aid of the Genetics Computer Group sequence 
analysis program, version 7.1 (Devereux et al., 1984), and 
20bp primers (4.6-1: GGAGACACGAGCCACTCAAG, 4.6-2: 
AGAGAACCCCCTCCAAGAGC) that flanked the region of the 
deletion were generated by the Macromolecular Analysis 
Facility (Loyola University Chicago, Maywood, IL) . The 
primers were used in the polymerase chain reaction (PCR) to 
amplify the sequence around the site of the deletion 
region. PCR reactions were optimized using the Bios 
Optimization System (Bios Laboratories, New Haven, CT) and 
consisted of 10µ1 of lOx Optitaq buffer G (40mM NaCl, lOmM 
Tris-HCl, pH 8.4, 0.01% gelatin, 0.1% Triton X-100, 1.SOmM 
MgCl 2 ) or 0 (lOrnM (NH4 ) 2 S04 , lOmM KCl, lOmM Tris-HCl, pH 
8.4, 0.01% gelatin, 0.1% Triton X-100, 3.75rnM MgCl 2 ) (Bios 
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Laboratories, New Haven, CT) , lOµM of each primer, 1.06µ1 
dNTP mix which contained 20mM of each deoxyribonucleotide: 
dGTP, dATP, dTTP and dCTP (Bias Laboratories, New Haven, 
CT), 4ng template for p4.6EP and 0.5ug template for patient 
DNA, 2U Taq DNA polymerase (Perkin Elmer Cetus, Norwalk, 
CT) and dH2 0 to 100µ1. PCR was carried out in an MJ 
Research Programmable Thermal Controller using a profile 
of: 94°C for 1 minute (denature), 64°C for 1 minute 
(anneal), 72°C for 1 minute (extend) for a total of 35 
cycles. 
In PCR products of patient DNAs, two bands resulted in 
those patients who were heterozygous for the deletion. 
Only one of the regions was the area of interest for 
sequencing. In order to isolate that one band, band-stab 
PCR was utilized (Kadokami et al., 1994; Bjourson et al., 
1992). PCR reactions consisted of 10 µl of lOx Optitaq 
buffer G or 0 (Bias Laboratories, New Haven, CT), lOµM of 
each primer, l.06µL dNTP mix (as above), 2U Taq DNA 
polymerase and dH2 0 to 100 µl. The template for these 
reactions was acquired as follows: an aliquot of the two-
banded PCR product was run out on a 1.5% agarose gel. The 
gel was stained with ethidium bromide, and viewed on a UV 
transilluminator (300nm) . Excess water was removed from 
the surface of the gel with Whatman 3MM paper and the 
appropriate band was stabbed or lifted out of the gel with 
a hypodermic needle which was then dipped with gentle 
agitation into a fresh PCR reaction mixture. PCR was 
carried out under the same conditions as above. 
Cycle Sequencing 
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PCR products were prepared for sequencing using the 
"wizard" PCR clean-up method (Promega Corporation, Madison, 
WI). Thermal cycle sequencing using the "fmol" kit 
(Promega Corporation, Madison, WI) and the dsDNA Cycle 
Sequencing system (Life Technologies, Inc., Gaithersburg, 
MD) were done following the manufacturer's instructions 
which involved a two-step process to prepare the samples 
for PCR. 
The dsDNA Cycle Sequencing system first step is 
labeling the primer: lpmol of primer, 2pmol of r 32 P ATP, 
1.0 µl 5x Kinase buffer, and 1.0 unit of T-4 kinase and 
dH2 0 to 5µ1 were mixed and incubated in a 37°C waterbath 
for 10 minutes; the kinase was then deactivated at 55°C for 
5 minutes. The reaction mixture consisted of: 5.0 µl 
labeled primer, 4.5µ1 lOx sequencing buffer, .033ng 
(50fmol) of template DNA, 1.23 units Taq polymerase and 
dH2 0 to 36µ1. 8µ1 of this mixture were added to tubes 
containing 2µ1/tube of appropriate termination mix: ddGTP, 
ddATP, ddTTP or ddCTP. The tubes were overlaid with 
silicone oil and spun. After PCR was completed 5µ1 of stop 
solution was added and the tubes spun. 
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The fmol kit started by labeling the primer: 5pmol 
primer, 5pmol y32 P ATP, 0.5µ1 lOx kinase buffer, and 2.5 
units of T-4 kinase to 5µ1 was mixed and incubated in a 
37°C waterbath for 30 minutes; the kinase was then 
deactivated at 90°C for 2 minutes. The reaction mixture 
consisted of: 1.5µ1 labeled primer, 5.0µ1 5x fmol buffer, 
235.3ng (500fmol) of template DNA and dH2 0 to 16µ1. To 
this tube 1.25 units of Taq polymerase were added, then 4µ1 
were added to tubes containing 2µ1/ tube of appropriate 
termination mix: ddGTP, ddATP, ddTTP or ddCTP. The tubes 
were overlaid with silicone oil and spun. After PCR was 
completed 3µ1 of stop solution was added and the tubes 
spun. 
PCR was carried out for either method in an MJ 
Research Programmable Thermal Controller using a profile 
of: a 95°C "hot-soak" for 3 minutes, 95°C for 30 seconds 
(denature) , 62°C for 30 seconds (annealing) , 72°C for 1 
minute (extension/ termination), repeating the 
denature/annealing/ extension/termination steps for 19 
cycles, then 95°C for 30 seconds (denature), 70°C for 1 
minute (extension/ termination), repeating this for 9 more 
cycles. The above two methods were utilized to sequence the 
deletion sites in the P4.6 clone and a patient with a short 
deletion. Comparison of the sequences of the short allele 
and the normal allele were then made. 
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Sequencing Gels 
Sequencing gels containing 8% acrylamide/bis (37.S:l) 
and 7M urea were used to obtain the sequencing data. To 
prepare the gel for casting, glass plates were cleaned 
using "clear Ivory" dishwashing detergent and rinsed with 
tap water. Excess water was removed by rinsing the plates 
with 9S% ethanol. The larger plate was then silanized 
using either Rain-X (Unelko Corporation, Scottsdale, AZ) or 
Gel Slick (AT Biochem, Malvern, PA) following the 
manufacturer's instructions to allow for easy separation 
following electrophoresis. One hundred twenty five mls of 
the 8% acrylamide/bis and urea mixture was filtered and 
degassed. Immediately before pouring, 800µ1 of fresh 10% 
ammonium persulfate and 20µ1 of TEMED were added to the gel 
mixture. The gel was poured between the plates using a 
60ml syringe and 18 1/2 gauge needle. The gel was run 
using lxTBE buffer and SSW of constant power. After 
electrophoresis, the sequencing gel was soaked for lS 
minutes in 10% glacial acetic acid/10% methanol to remove 
the urea. The gel was then transferred to Whatman 3MM 
filter paper by established methods (Kozak et al., 1991), 
dried in a gel dryer (Bio-Rad laboratories, Hercules, CA) 
for 3 hours, 20 minutes and autoradiographed. The sequence 
was read a minimum of 3 times from independent gel runs in 
order to confirm the sequence accuracy. Sequence analysis 
was done with the aid of the VAX network system (Loyola 
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University Chicago), the Genetics Computer Group sequence 
analysis program, version 7.1 (Devereux et al., 1984), and 
the Hibio DNAsis DNA sequence analysis system, seventh 
version (Hitachi, 1990). 
CHAPTER IV 
RESULTS 
Localization of Deletion in Site 2 
The first step in characterizing the Site 2 locus (4.6kb 
Hind III fragment) was to approximately localize the region 
where the deletions occur. A genomic clone containing Site 
2 (p4.6) has previously been isolated (Cammarata, 1994), and 
its restriction map is shown in Figure 1. The 1. 4kb 
EcoRI/SstI fragment of this clone was 32 P-labeled by nick 
translation and used to probe blots of restricted genomic 
DNAs from two different normal heterozygous individuals and 
a patient with a homozygous 200bp deletion at Site 2. Single 
and double digest combinations were performed in order to 
delimit the deletion site. A single digest using Hind III 
was done, as well as various double digests, working inward 
toward the helical coding region (Figure 1) . Smaller and 
smaller regions were digested to narrow down the location of 
the deletion. The goal was to locate where the fragment in 
the patient and the normal become the same size. The Hind 
III digest resulted in one fragment of 4.4kb in the patient 
and two fragments of 4. 6kb and 4. 3kb respectively in the 
normal (Figure 2A, lanes 9 and 10). The Hind III+Pst I 
digest resulted in one fragment of 3.7kb in the patient and 
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two fragments of sizes 3. 9kb and 3. 6 kb in the normal 
individual (Figure 2A, lanes 7 and 8) . The Hind III+PvuII 
digest resulted in one fragment of 2.8kb in the patient and 
two fragments of sizes 3.0kb and 2.7kb in the normal 
individual (Figure 2A, lanes 5 and 6) . In the second set of 
digests, done to confirm the data, one fragment of 2.8kb in 
the patient and two fragments of sizes 3.0kb and 2.7kb were 
also seen in the normal (Figure 2B, lanes 3 and 4) . The Hind 
III+EcoRI digest resulted in one fragment 2.3kb in size in 
both the patient and normal (Figure 2A, lanes 3 and 4) . The 
second set of digests resulted in one fragment of 2.3kb in 
both the patient and normal (Figure 2B, lanes 1 and 2). The 
HindIII+BglI digest resulted in one fragment 2.0kb in size 
for both the patient and normal (Figure 2A, lanes 1 and 2). 
The deletion was determined to be in the region between the 
EcoRI and PvuII sites. This is the region where the second 
allele, which contains the deletion is lost. The PvuII 
digest still had two bands and a smaller patient band, but in 
the Eco digest the bottom normal band is lost and the normal 
and patient band become the same size. This region contains 
the triple helical-like coding region of Site 2 (see Figure 
1) (Cammarata, 1994) . Because of the collagen-like nature of 
this region, and the fact that deletions can occur here, the 
region was sequenced to determine its characteristics. 
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Sequencing of the 4.6 Subclone 
At Site 2, deletions of heterogeneous size are 
significantly more prevalent in OI Type III patients than in 
unaffected individuals (Cammarata et al., 1991; Doering et 
al., 1987). Because the above results showed the deletion 
was located in the collagen-like helical coding region of 
Site 2 (see Figure 1) the detailed sequence of this region 
is important to know. Previous characterization of 735bp of 
this region found it to be repetitive in nature and very GC 
rich (Cammarata, 1994) . This led to problems in sequencing 
the entire region. A "ladder" effect from all the secondary 
structure resulted when trying to sequence farther in than 
200bp from the primer. Internal primers based on the new 
sequence usually allows for further sequence determination 
and helps reduce the premature termination that results from 
secondary structure. However, the repetitive nature of the 
sequence (Cammarata, 1994) did not allow for identification 
and use of internal primers. To allow for sequencing, the 
EcoRI/SmaI fragment was isolated and subcloned as a 1.Skb 
EcoRI/SmaI fragment into a pGEM7Zf+ vector (P4. 6ME) (see 
Figure 3C), so that nested deletions could be generated to 
allow sequencing of the entire region extending beyond 735bp 
to 899bp, which is the entire repeat region. 
Generation of Nested Deletions 
The "Erase-A-Base" 
Corporation, Madison, WI) allowed 
nucleotides from the EcoRI digested 
subclone by employing exonuclease III. 
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system (Promega 
serial removal of 
end of the P4.6ME 
A series of clones is 
created by removing samples at timed intervals which bring 
the 3' sequences closer to the primer. This method allowed 
the creation of a series of subclones containing overlapping 
sequences that encompassed the remaining portion of the 
triple helical coding region (see Figure 3D) . The deletion 
subclones P4.6ME-9 (325bp), P4.6ME-13 (225bp), and P4.6ME-18 
(175bp) were used to generate the nucleotide sequence from 
position 535 through to position 899 which includes the 
remainder of the helical coding region. Sequence was 
obtained using the "Ampli-Taq" sequencing kit (Perkin-Elmer 
Cetus) . This kit was utilized because it uses Taq 
polymerase, which is a very heat stable enzyme (45-72°C), 
which was needed to reduce secondary structure in the GC rich 
areas. Figure 4 shows a representative example of the 
sequence information obtained from 8% acrylamide sequencing 
gels of the subclones. The sequence generated by the above 
methods will be referred to as "NT899" (see Figure 5) . 
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Results of the Sequencing Data 
The nucleotide sequence. Analysis of the sequence shows 
that from position 128 to 775 there are 34 direct repeats 
composed of the consensus 18 nucleotide repeating unit: AAG 
ACC AGC AGC CCA GAC. Each of the repeating units have an 
average of 93.3% identity to this sequence, yet have 
substantial heterogeneity. There are three interruptions 
that are 9 nucleotides long, and these insertions, which 
disrupt the direct repeats, begin with a PvuII restriction 
site (indicated by carats and underlined in Figure 6). 
Although these insertions interrupt the direct repeats, their 
presence results in the coding of two perfect triple helical 
9-mers with the amino acid sequence (Gly-X-Y) 2 in the reverse 
translation at these locations. There are also thymidine 
insertions which interrupt the direct repeats at various 
locations in the NT899 sequence (see Figure 6) . 
The basic repeating unit is not itself a strict triplet 
repeat sequence, but by substituting "C" for "A", in the 
fourth position it becomes one. Very few repeats contain 
this subs ti tut ion though. On the occasions when it does 
occur, a "T" insertion also occurs in that repeat making it 
19bp long. In the repeats with "T" insertions subsequent to 
a PvuII site, two perfect triplet repeats adjacent to each 
other also occur. These are also in the reverse translation. 
Sequence analysis. Computer analysis of the sequence 
shows there is 63% GC content, which is consistent with 
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collagen sequences (Bernard et al., 1983). Analysis of the 
helical coding region sequence was performed with the aid of 
the GCG "bestfit", "overlap" and "fasta" programs (Devereux et 
al., 1984). This allowed sequences to be chosen for DNA 
primers for PCR reactions. The desired primers would flank 
the repetitive region to allow amplification of the deletion 
region (see Figure 6) . The sequences necessary for primers 
are non-repetitive, non-complementary sequences of 
approximately 20-25bp in length (Innis et al., 1990). 
Fifteen primers were originally chosen from the regions 
flanking the repeat clusters of NT899 for analysis. The 
bestfit program was used to make an optimal alignment of the 
best segment of similarity between each primer and NT899. It 
does this by inserting gaps to maximize the number of 
matches. You want a primer with the smallest number of 
bestfits, so it will not be complementary with multiple 
places in the sequence. Both strands of the sequence are 
searched using this method. You can thus also determine that 
the primer will amplify in the proper orientation (5' or 3'), 
most efficaciously. 
Once the primers are narrowed down by bestfit, you run 
them on the overlap program. It compares two sets of DNA 
sequences to each other in both orientations looking for 
overlaps between sequences 
similarity (see Figure 7) . 
rather than simply regions of 
The lower the percentage of 
overlap found, the safer it would be to say that you have 
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only one site that would bind the primer. Anything below 50% 
overlap is considered acceptable (Devereux et al., 1984). If 
possible, overlap should not be on the end of the primer in 
the orientation of amplification, to avoid the risk of 
misamplification. Also, if the overlap is in the 
complementary orientation, it is not that big a concern 
because you will only be amplifying or sequencing in the 
direction for which the primer was chosen. 
The final check of the primers was to run a 11 fas ta 11 
analysis. This searches for similarities between one 
sequence and any other sequence, aligning the search set 
against the query set for display Figure 7) It optimizes 
the length of overlap and minimizes gaps to only a few 
nucleotides, finding the portion of sequence with the highest 
identity. The resulting primers 4. 6-1: GGAGACACGAGCCACTCAAG 
and 4.6-2: AGAGAACCCCCTCCAAGAGC flanked the region of the 
deletion (see Figure 6) . These primers were chosen because 
they had the lowest amount of overlap to the NT899 sequence 
in the orientation for amplification, had no repetitive 
sequence, and had the least match to the NT899 sequence- in 
the complementary orientation. 
Primer 4.6-1 was located between bp88 and 107 of NT899 
(see bold underlined primer in Figure 6) . Analysis of the 
first primer showed it had only 28-30% overlap to any site in 
the NT899 sequence in the forward direction, except for one 
site with 40% overlap. None of the regions of overlap were 
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on the end of the primer. It had one region of 30% overlap 
in the reverse (non-amplifying) direction. This was 
acceptable since PCR and DNA sequencing would only be in the 
forward direction (left to right in Figure 6) and not the 
reverse direction with this primer. Primer 4.6-2 was located 
between bp781 and 800 of NT899 (see bold underlined primer in 
Figure 6) Analysis of this primer showed it had only 30-35% 
overlap to any sites in the NT899 sequence in its 
amplification direction (right to left in Figure 6) It had 
one region of 30% overlap on the opposite strand (non-
amplifying direction) that was within the primer, not on the 
end. This was acceptable since this primer would only be 
used to generate PCR products and DNA sequence in the 
amplification direction. The primers had no overlap with 
each other (data not shown) . 
PCR of the p4.6EP Subclone Repeat Region 
The primers were used in the polymerase chain reaction 
(PCR) to amplify the sequence around the site of the deletion 
region in the p4.6EP subclone. PCR reactions were optimized 
using the Bias Optimization System (Bias Laboratories, New 
Haven, CT) which varies Mg++ concentrations (range O. 75-
3. 7 5mM) in three different buffers based on KCl, NaCl or 
(NH4 ) 2 804 • Mg++ concentration is a key variable in controlling 
specificity and yield of PCR. The ionic environment provided 
by the buffer is also critical to the specificity of 
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amplification. Amplification proceeded with a thermal 
profile specific to the locus and products were 
electrophoresed on agarose to select the buff er yielding the 
optimum balance of specificity and yield (data not shown) . 
Buffers G(40mM NaCl, lOmM Tris-HCl, pH 8.4, 0.01% gelatin, 
0 .1% Triton x-100, 1. 50mM MgCl 2 ) or 0 (lOmM (NH4 ) 2 804 , lOmM 
KCl, lOmM Tris-HCl, pH 8.4, 0.01% gelatin, 0.1% Triton X-100, 
3.75mM MgCl 2 ) were used to amplify the repeat region. 
Reactions contain 4ng of the p4. 6EP clone DNA, which is 
amplified with Taq polymerase using the following profile: 
94°C for 1 minute, 64°C for 1 minute, 72°C for 1 minute, for 
35 cycles. 
The p4.6 site 2 clone was amplified first to make sure 
the primers were specific and resulted in the proper size 
fragment. The resulting fragment was approximately 790bp 
long (see Figure 8, lane 3). This is the same size as the 
tandem repeat region flanked by the chosen primers. Genomic 
DNA from an unaffected individual was then amplified. Two 
fragments resulted, one 790bp in size and one 500bp in size 
(see Figure 8, lane 2) . The smaller fragment is the one 
containing the deleted region. This verified the results 
from the Southern blots in Figure lA and B, that there are 
two alleles in the normal individual and one contains an 
approximately 300bp deletion in the triple helical coding 
region. 
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PCR of Patient DNA 
The constructed primers were then used to amplify the 
repeat region from the genomic DNAs of five additional OI 
patients known to have Site 2 deletions, three of which are 
shown here (see Figure 8, lanes 4, 5 and 6). Four out of the 
five patient DNAs that were PCR amplified were either 
heterozygous or homozygous for deletions in the repeat 
region. A possible explanation for the patient with only one 
full-length band could be that the deletion region expanded 
outside the tandem repeat region or may be located elsewhere 
in the Site 2 gene. Deletions at the site result in shorter 
than normal fragments being generated by the PCR. As a 
result, comparing the sizes of the DNA fragments generated 
from each sample permits identification of individuals with 
a deletion and indicates what size deletion they have. One 
patient (lane 6) was homozygous for a deletion of 
approximately 200bp. The range of sizes of the deletion in 
the three heterozygous patients from 60-340 bp in length. In 
all cases but one, shorter than normal fragments resulted, 
indicating that Site 2 deletions are usually confined to the 
region containing the tandem repeat clusters. 
Direct Sequencing of PCR Products 
In order to sequence PCR products, they must be free of 
contaminating amplification primers and nucleotides. The 
wizard PCR preps DNA purification system (Promega, Madison, 
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WI) was used to prepare PCR products for sequencing. It 
purifies double-stranded PCR amplified DNA away form 
contaminants, including primer-dimers and amplification 
primers. The DNA is eluted from the Magic PCR preps resin 
(Promega Corporation, Madison, WI) in water free of salt or 
macromolecular contaminants. Samples were then ready for 
direct sequencing. 
Because the sequence is very GC rich and repetitive in 
nature, sequence extension can be difficult. There are also 
problems with secondary structure causing premature 
termination. Thus, two methods were investigated for direct 
cycle sequencing to determine which would give better 
results. The first was the dsDNA Cycle Sequencing system 
(Life Technologies, 
fmol of template 
polymerase. The 
Inc., Gaithersburg, MD) which uses 50 
and an end-labeled primer with Taq 
second was the Fmol kit (Promega 
Corporation, Madison, WI) which uses 500 fmol of template, an 
end-labeled primer and Taq polymerase. The kits were very 
similar except for the 100-fold difference in the starting 
template (see Materials and Methods) . The fmol kit was 
chosen to sequence a majority of the patient DNA because it 
resulted in clearer, more readable sequence further in. 
Optimization experiments were done increasing the dsDNA 
method starting template amount to see if that improved the 
quality of the results, It did not. Fmol allowed for clear 
sequencing of the repeat region of patient DNA far enough in 
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to narrow down the region where the deletion was located. 
However, due to the repetitive nature of the DNA and lack of 
restriction sites as landmarks, it made determining the exact 
endpoints of the deletion impossible. 
PCR sequencing reactions were carried out for either 
method using the following profile: 95°C for 3 minutes, 95°C 
for 30 seconds, 62°C for 30 seconds, 72°C for 1 minute, 
repeating all but the first step for 19 cycles, then 95°C for 
30 seconds, 70°C for 1 minute, for 9 more cycles. 
Sequencing of the p4.6EP Subclone Repeat Region 
Cycle sequencing was first performed on the p4. 6EP 
subclone to verify that the region of interest was being 
properly amplified, and to optimize methods (see Figure lOA) . 
Both direct cycle sequencing methods were used, with the Fmol 
method generating most of the sequence. The sequence 
obtained was an exact match to NT899 (see Figure 5) . This 
verified that the sequence that would be obtained from the 
tandem repeat region of the patient DNA would be reliable. 
Sequencing of the Repeat Region in Patient DNA 
In order to sequence the patient DNA, the two fragments 
must be separated to isolate only the band containing the 
deleted allele. This was done using bandstab PCR (Kadokami 
et al., 1994; Bjourson et al., 1992). An aliquot of the PCR 
amplified patient DNA was run out on a high percentage 
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agarose gel (1. 5%) . The gel was stained with ethidium 
bromide, and viewed on a UV transilluminator (300nm) . Excess 
water was removed from the surf ace of the gel and the lower 
band was stabbed from the gel with a hypodermic needle which 
was then agitated into a normal PCR reaction mixture that was 
prepared without any template. PCR was carried out under the 
same conditions as above. An aliquot of the reaction was run 
out on an agarose gel to verify amplification. Figure 9 
shows these results. Lane 2 is an aliquot of the original 
patient genomic amplification, showing the two bands of 
approximately 790bp and 700bp in size. Bandstab results are 
shown in lanes 3 and 4. The top band is in lane three and 
the bottom band (containing the deletion) is in lane 4. This 
shows the deletion to be approximately 90bp in size. 
The bandstab PCR reaction for the deleted allele was 
then cleaned up in order to remove contaminants and 
extraneous primer by the "wizard" PCR clean-up method 
(Promega Corporation, Madison, WI) . DNA cycle sequencing 
reactions were then performed on this fragment and run on 8% 
acrylamide sequencing gels. Figure lOB is an example of the 
patient sequence obtained by this method. The region shown 
is the same region as that in Figure lOA from the p4.6EP 
subclone. The sequences match exactly. The PCR sequencing 
reactions accurately amplified the patient template, 
generating sequence of the repeat/deletion region. This 
again verified that this was an effective, reliable method of 
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determining the sequence of patient DNA. 
The deleted allele for this patient ( 3C2) was then 
sequenced to the extent possible as above and compared to the 
entire NT899 sequence and the p4. 6 PCR product sequence. The 
sequence is shown in Figure 11. Nucleotides sequenced are 
shown aligned along the NT899 sequence for comparison. The 
available regions of patient sequence matched NT899 exactly. 
No point mutations were present in the patient sequence. The 
region of the deletion is represented by the cross hatches. 
The deletion region of approximately 125bp is shown in the 
repeat aligned sequence of NT899 in Figure 12. This is the 
maximum size of the deletion region. Since the sequence 
could not be reliably read any further in from the primers. 
The exact deletion endpoints could not be determined due to 
the repetitive nature of the sequence and lack of restriction 
sites to use as landmarks. It was difficult to tell where 
one repeat started and ended as you got further into the 
deletion region. PCR of the genomic patient DNA gave a 
deletion size of approximately 90bp in length (see Figure 9) . 
Thus the sequencing results and the PCR data indicate that 
the deletion in this patient is approximately 90-125bp in 
length. 
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Figure 1. Restriction map of 4.6kb cloned fragment showing 
the deletion location. 
The new collagen-like locus on chromosome 17 was cloned from 
a chromosome specific library as a 4.6kb HindIII restriction 
fragment. Restriction sites for the indicated enzymes are 
shown. Fragment sizes in base pairs are indicated. The 
location of Alu repetitive sequences are also indicated (*). 
The locus contains a short triple helical coding region that 
cross-hybridizes the the pro-a2(I) cDNA, Hf32 (bold line). 
The region where ·deletions occur (as indicated by the bold 
arrow) is located between the EcoRI and PvuII restriction 
sites. This is the same sequence where the 18bp tandem 
repeats are located. The direction of transcription in this 
locus is indicated by the horizontal arrow. 
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Figure 2. Localization of deletion region. 
A: Restriction digests of DNAs from a patient with a 
homozygous 200bp deletion at Site 2 and from a normal 
heterozygous individual were hybridized to the EcoRI/SstI 
fragment of p4.6. 
Lane 1, patient DNA digest: HindIII+BglI 
Lane 2 I normal DNA digest: Hind III+BglI 
Lane 3 f patient DNA digest: HindIII+EcoRI 
Lane 4, normal DNA digest: HindIII+EcoRI 
Lane 5, patient DNA digest: HindIII+PvuII 
Lane 6, normal DNA digest: HindIII+PvuII 
Lane 7, patient DNA digest: HindIII+PstI 
Lane 8 f normal DNA digest: HindIII+PstI 
Lane 9, patient DNA digest: HindIII 
Lane 10, normal DNA digest: HindIII 
B: Restriction digests of DNAs from a patient with a 
homozygous 200bp deletion at Site 2 and from a different 
normal heterozygous individual were hybridized to the 
EcoRI/SstI fragment of p4.6. 
Lane 1, patient DNA digest: HindIII+EcoRI 
Lane 2, normal DNA digest: HindIII+EcoRI 
Lane 3, patient DNA digest: HindIII+PvuII 
Lane 4, normal DNA digest: HindIII+PvuII 
Comparing the fragments obtained in the patient to that in the 
normal control allowed localization of the deletion to the 
small region between PvuII and EcoRI sites. 
This is seen as the loss of the second band in the normal 
heterozygous individual, and both normal and patient having 
one band of the same size. 
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A. 












Figure 3. Schematic diagram of the clones, subclones and PCR 
products used to characterize the deletion site. Only a 
portion of the vectors are shown in the diagrams. 
A: p4 . 6, the pUC13 vector containing the 4 . 6kb Hind I I I 
fragment. 
B: p4.6EP, the pUC13 vector containing the 1.6kb EcoRI/PstI 
helical coding fragment. 
C: p4.6ME, pGEM7Zf+ vector containing the 1.Skb EcoRI/SmaI 
triple helical coding fragment. 
D: Linearized p4.6ME and the resulting nested deletion 
subclones generated by the "Erase-A-Base" system. These 
deleted subclones were recircularized prior to sequencing. 
E: PCR product 4. 6EP, The PCR product generated using the 
constructed pair of PCR primers that flank the tandem cluster 
on the p4.6 EcoRI/PstI template. 
F: PCR product Pt3C2, The PCR product generated using the 
constructed pair of PCR primers that flank the tandem cluster 
on a heteozygous patient genomic DNA template. 
Sizes of fragments are indicated in base pairs. 
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Figure 4. 8% acrylamide sequencing gel of Site 2 nested 
deletions. 
A typical example of the sequence generated using the "Ampli-
Taq" kit. 102 nucleotides can be read as pictured here 
(position 643 to 745 of the NT899 sequence) . The PvuII site 
sequence at position 680 is indicated. The letters at the top 








1 GAATTCCAGT CACTCCCTCC AGGAGACACA CCAGCAGTGG TCAGGAAGCA 
51 AGTCCACCAC AGCCTTCTGG AAAGGTCTCT AGTCTCAGGA GACACGAGCC 
* 
101 ACTCAAGCCT CCCACATGCC ACCAAAGAAG ATAAGCTGGC CCAGAGAAGA 
151 CCAGCAGCCC AGAGAAGACC AGCAGCCTGG ACAAGACCAA CAGCCCAGAC 
Ava II AvaII 
201 ATAGACCAGC AGCCCAGAAA GGACCAGCAG CCCAGACAGG ACCAGCAGCC 
251 CAGGCAAGAC CAGCAGCCTG GACAAGACCA GCAGCCTGGA CAAGACCAAC 
AvaII 
301 AGCCCAGACA TAGACCAGCA GCCCAGACAG GACCAACAGC CCAGACATAG 
AvaII 
351 ACCAGCAGCC CAGACAGGAC CAGCAGCCCA GACAAGACCA GCAGCCTGGA 
PvuII 
401 CAAGAACAGC TGGCCCAGCA GCCCATACAA GACCAGCAGC CCAGATATAG 
451 CCCAGCAGCC CAGACATAGC CCAGCAGCCC AGACAAGACC AGCAGCCCAG 
PvuII 
501 ACAAGACCAG CAGCCTGGAC AAGACCAGCA GCCAGGATAA GAACAGCTGG 
551 CCCAGCAGCC CATACAAGAC CAGCAGCCCA GATATAGCCC AGCAGCCCAG 
601 ACATAGCCCA GCAGCCCAGA CAAGACCAGC AGCCCAGACA AGACCAGCAG 
PvuII 
651 CCCGGACAAG ACCAGCAGCC AGGATAAGAA CAGCTGGCCC AGCAGCCCAT 
701 ACAAGACCAG CAGCCCAGAC ATAGCCCAGC AGCCCAGACA AGACCAGCAG 
* 
751 CCCAGACAAG AACCAATCTG CCCAGGCTGC TCTTGGAGGG GGTTCTCTCA 
801 GGATTCTCAG GCTCAAAGTA GGCCGAGCCT GGGTCATCAC CACTCCGGCA 
AvaII 
851 GCCCAAGTGG GACCTCCTGG GACAGGCTTC ATCTCCGCAC TTGCAGGAG 
Figure 5. Complete nucleotide sequence of NT899. 
Selected restriction sites are indicated above their 
recognition sequence. Asterisks indicate the beginning and 
end of the tandem repeat clusters. Numbers on the left margin 
indicate the nucleotide position at the start of the line. A 
space is inserted after every tenth nucleotide for easier 
reading. 
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Figure 6. Sequence of NT899 aligned to illustrate the 18bp 
nucleotide direct repeats. 
There are 34 repeats with a minimum of 83.4% identity to the 
basic repeat and 3 brief insertions of 9 nucleotides each. 
Single thymidine insertions also occur periodically. The 
carats indicate the exact location of the insertions which 
have been removed and placed above the sequence they 
interrupt. The primers used to amplify the region are 
indicated by the bold underline. Numbers to the left indicate 
the re spec ti ve repeat. Numbers to the right indicate the 





1 A A G A T A A G evG G e e e A G A G 146 
2 AAGAeeAGeAGeeeAGAG 
3 A A G A e e A G e A G e e T G G A e 182 
4 AAGAeeAAeAGeeeAGAe 
T 




7 A G G A e e A G e A G e e e A G G e 255 
8 AAGAeeAGeAGeeTGGAe 
9 A A G A e e A G e A G e e T G G A e 291 
10 A A G A e e A A e A G e e e A G A e 
T 
11 AvA G A e e A G e A G e e e A G A e 328 
AVAII 
12 A G G A e e A A e A G e e e A G A e 
T 
13 AvA G A e e A G e A G e e e A G A e 365 
AVAII 
14 A G G A e e A G e A G e e e A G A e 
15 A A G A e e A G e A G e e T G G A e 401 
PVUII 
CAGCTGGee 
16 A A G A Ave A G e A G e e e A T A e 
17 A A G A e e A G e A G e e e A G A T 446 
T 
18 AvA G e e e A G e A G e e e A G A e 
T 
19 AvA G e e e A G e A G e e e A G A e 484 
20 A A G A e e A G e A G e e e A G A e 
21 A A G A e e A G e A G e e T G G A e 520 
22 A A G A e e A G e A G e e A G G A T 
PVUII 
eAGCTGGee 
23 A A G A Ave A G e A G e e e A T A e 565 
24 A A G A e e A G e A G e e e A G A T 
T 
25 AvA G e e e A G e A G e e e A G A e 602 
T 
26 AvA G e e e A G e A G e e e A G A e 
27 A A G A e e A G e A G e e e A G A e 639 
28 A A G A e e A G e A G e e e G G A e 
29 A A G A e e A G e A G e e A G G A T 675 
PVUII 
CAGCTGGee 
30 A A G A Ave A G e A G e e e A T A e 
31 A A G A e e A G e A G e e e A G A e 72 0 
T 
32 AvA G e e e A G e A G e e e A G A e 
33 A A G A e e A G e A G e e e A G A e 757 
34 A A G A A e C A A T e T G e e e A G 
GeTGCTCTTGGAGGGGGTTCTCTCAGGATTeTeAGGeTeAAAGTAGGe 823 
eGAGeeTGGGTeATeAeeAeTeeGGeAGeeeAAGTGGGAeeTeeTGGG 871 
AeAGGeTTeATeTeeGCAeTTGAeGGAG 8 9 9 
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A. 
PRIMER #1 FROM NT899 SEQUENCE 
TO: NT899.seq;l 
P4.6 M/E deletion subclone sequence 
SCORES Initl: 80 Initn: 80 Opt: 80 





NT8 9 9 II II I II II I II I I I I I I I I 
I I I I I I I I I I I I I I I I I I I I 
60 
CACAGCCTTCTGGAAAGGTCTCTAGTCTCAGGAGACACGAGCCACTCAAGCCTCCCACAT 
60 70 80 90 100 110 
GCCACCAAAGAAGATAAGCTGGCCCAGAGAAGACCAGCAGCCCAGAGAAGACCAGCAGCC 
120 130 140 150 160 170 
B. 
PRIMER #2 FROM NT899 SEQUENCE 
TO: NT899.seq;l 
P4.6 M/E deletion subclone sequence 
SCORES Initl: 80 Initn: 80 Opt: 80 





NT899 I I I I I I I I I I I I I I I I I I I I 
I I I I I I I I I I I I I I I I I I I I 
AGCCCAGACAAGAACCAATCTGCCCAGGCTGCTCTTGGAGGGGGTTCTCTCAGGATTCTC 
760 770 780 790 800 810 
AGGCTCAAAGTAGGCCGAGCCTGGGTCATCACCACTCCGGCAGCCCAAGTGGGACCTCCT 
820 830 840 850 860 870 
Figure 7. Primer pattern analysis ~esults. . 
A: Fasta computer analysis of Primer 1 showing comp~ete 
identity only with the region that exactly matches the primer 
selected. 
B: Fasta computer -~nalysis of Primer 2 showing complete 













1 2 3 4 5 6 
Figure 8. PCR amplification of repeat region. 
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-790 
Using primers synthesized from areas surrounding the tandem 
repeats in Site 2, PCR amplification of the deletion regions 
was possible. Lane 1: molecular weight marker, Lane 2: 
amplification of tandem repeat region in a unaffected 
individual (BenVen), Lane 3: amplification of tandem repeat 
region in Site 2 clone (p4.6EP), Lane 4, 5, 6: amplification 
of tandem repeat region in three OI patients with ·Site 2 













2 3 4 
-790 
-700 
Figure 9. Bandstab amplification of deleted region. 
62 
In order to sequence the deletion region in patient DNA, it 
was necessary to determine which allele contained the 
deletion. Bandstab PCR was used to amplify each individual 
allele and direct sequencing of the PCR-amplif ied fragment 
from the deleted allele was performed. Lane 1: molecular 
weight marker, Lane 2: amplification of tandem repeat region 
in OI patient, Lane 3: bandstab amplification of _ larger 
patient allele, Lane 4: bandstab amplification of smaller 
patient allele. 
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Figure 10. PCR direct sequencing acrylamide sequencing gels. 
8% acrylamide sequencing gel of: 
A: p4.6EP PCR product 
B: bandstab amplification of deleted patient allele using the 
"dsDNA cycle sequencing system". The AvaII sites at positions 
220 and 237 respectively are indicated.116 nucleotides can be 
read as pictured here (position 160 to 276 of the NT899 
sequence) . The letters at the top indicate the nucleotide 











1 ---------- ---------- ---------- ---------- ----------
51 ---------- ---------- ---------- -------GGA GACACGAGCC 
* 
101 ACTCAAG--- CCCACATGCC ACCAAAGAAG ATAAGCTGGC CCAGAGAAGA 
151 CCAGCAGCCC AGAGAAGACC AGCAGCCTGG ACAAGACCAA CAGCCCAGAC 
Ava II Ava II 
201 ATAGACCAGC AGCCCAGAAA GGACCAGCAG CCCAGACAGG ACCAGCAGCC 
251 CAGGCAAGAC CAGCAGCCTG GACAAGACCA GCAGCCTGGA CAAGACCAAC 
Ava II 
301 AGCCCAGACA TAGACCAGCA G///////// ////////// ////////// 
Ava II 
351 ////////// ////////// ///Ill//// ////////// //////Ill/ 
PvuII 
401 ////////// ////////// ////////// ////////// //////ATAG 
451 CCCAGCAGCC CAGACATAGC CCAGCAGCCC AGACAAGACC AGCAGCCCAG 
PvuII 
501 ACAAGACCAG CAGCCTGGAC AAGACCAGCA GCCAGGATAA GAACAGCTGG 
551 CCCAGCAGCC CATACAAGAC CAGCAGCCCA GATATAGCCC AGCAGCCCAG 
601 ACATAGCCCA GCAGCCCAGA CAAGACCAGC AGCCCAGACA AGACCAGCAG 
PvuII 
651 CCCGGACAAG ACCAGCAGCC AGGATAAGAA CAGCTGGCCC AGCAGCCCAT 
701 ACAAGACCAG CAGCCCAGAC ATAGCCCAGC AGCCCAGACA AGACCAGCAG 
* 
751 CCCAGAC--- ---------- --------GC TCTTGGAGGG GGTTCTCT--
801 ---------- ---------- ---------- ---------- ----------
Ava II 
851 ---------- ---------- ---------- ---------- ---------
Figure 11. Schematic diagram of 4. 6kb clone sequence and 
patient DNA sequence aligned. 
Restriction sites are indicated above their recognition 
sequence as they were in NT899. Portions represented by lines 
were not sequenced in the patient. The region represented by 
the bold cross hatches indicates the region where the deletion 
is located. Actual endpoints are estimated. Asterisks 
indicate the beginning and the end of the tandem repeat 
clusters. Bold, underlined nucleotides indicate the primers 
used to amplify the repeat region and cycle sequence. Numbers 
on the left margin indicate the nucleotide position at the 
start of the line. A space is inserted after every tenth 
nucleotide for easier reading. 
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Figure 12. Schematic diagram of direct repeats in NT899 
indicating deletion region. 
Cross hatches indicate the deletion region. Bold, underlined 
nucleotides indicate the primers used for amplification and 
sequencing. Numbers to the left indicate the respective 
repeat. Numbers to the right indicate the nucleotide 





1 A A G A T A A G CvG G C C C A G A G 14 6 
2 A A G A C C A G C A G C C C A G A G 
3 A A G A C C A G C A G C C T G G A C 182 
4 AAGACCAACAGCCCAGAC 
T 




7 A G G A C C A G C A G C C C A G G C 255 
8 AAGACCAGCAGCCTGGAC 
9 A A G A C C A G C A G C C T G G A C 291 
10 A A G A C C A A C A G C C C A G A C 
T 
11 AvA G A C C A G C A G I I I / / / I 328 
AVAII 
12 I I I I I I I I I I I I I I I I I I 
I 
13 /v/ I I I I I I I I I I I I I I I I 365 
AVAII 
14 I I I I I I I I I I I I I I I I I I 
15 I I I I I I I I I I I I I I I I I I 4 01 
PVUII 
///////// 
16 I I I I /v I I I I I I I I I I I I I 
11 I I I I I I I I I I I I I I I I I I 446 
T 
18 AvA G C C C A G C A G C C C A G A C 
T 
19 AvA G C C C A G C A G C C C A G A C 484 
20 A A G A C C A G C A G C C C A G A C 
21 A A G A C C A G C A G C C T G G A C 520 
22 A A G A C C A G C A G C C A G G A T 
PVUII 
CAGCTGGCC 
23 A A G A AvC A G C A G C C C A T A C 565 
24 A A G A C C A G C A G C C C A G A T 
T 
25 AvA G C C C A G C A G C C C A G A C 602 
T 
26 AvA G C C C A G C A G C C C A G A C 
27 A A G A C C A G C A G C C C A G A C 639 
28 A A G A C C A G C A G C C C G G A C 
29 A A G A C C A G C A G C C A G G A T 675 
PVUII 
CAGCTGGCC 
30 A A G A Ave A G c A G c c c A T A c 
31 A A G A C C A G C A G C C C A G A C 720 
T 
32 AvA G C C C A G C A G C C C A G A C 
33 A A G A C C A G C A G C C C A G A C 757 
34 A A G A A C C A A T C T G C C C A G 
GCTGCTCTTGGAGGGGGTTCTCTCAGGATTCTCAGGCTCAAAGTAGGC 823 
CGAGCCTGGGTCATCACCACTCCGGCAGCCCAAGTGGGACCTCCTGGG 871 




This work involves characterization of the deletions in 
a newly discovered human collagen-like locus associated with 
osteogenesis imperfecta. Spontaneous deletions of 
heterogeneous size occur at the Site 2 locus more frequently 
in OI Type III patients than in normal individuals (Doering 
et al., 1987). This suggests that the defect in the 
structure of the protein coded for by Site 2 can contribute 
to the OI phenotype. The goal of this study was to locate 
the deletion site in the 4.6kb Hind III Site 2 fragment, and 
analyze the molecular structure of this region in affected 
individuals. This allowed the deletion to be more precisely 
localized and suggested a mechanism for the frequent 
occurrence of deletions at this site. The PCR methods 
developed here will also be useful in eventual screening 
programs for identifying individuals carrying deletions at 
Site 2. 
Region of Deletion 
Initially the deletion in the Site 2 locus was localized 
by Southern blotting to the region between the EcoRI and 
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PvuI I sites in one patient (see Figure 1) . This is the 
collagen-like helical coding region. The full sequence of 
this region revealed 34 direct repeats composed of an 18bp 
consensus repeating unit (see Figure 7) . To determine 
whether this repeat region is the major site for deletions, 
primers were synthesized that flanked the region, and PCR was 
performed on a normal individual, and multiple OI Type III 
patients. Four out of five patients amplified were either 
heterozygous or homozygous for a deletion in this region. 
The deletions were of heterogeneous size from patient to 
patient ranging from 60-340bp in length. The one patient 
that only had one normal-sized fragment by PCR could have a 
Site 2 deletion that extends outside the tandem repeats. 
Deletions are often found that extend from tandemly repeated 
sequences into adjacent regions (Willing et al., 1988; 
Zuliani et al., 1990). In any case, these PCR results 
demonstrate that Site 2 deletions are primarily localized to 
the cluster of 18bp repeats. Direct sequence data obtained 
from one patient indicates that the deletion is actually in 
the tandem repeat cluster and not in immediately adjacent 
sequences (see Figure 11 and 12). The patient sequence also 
contained no point mutations. 
Repetitive Nature of the Sequence 
Repetitive sequences with relatively short basic repeat 
units (2-25 nucleotides) are known to be responsible for 
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deletions which lead to length polymorphisms (Stoker et al., 
1985; Lee et al., 1991; Sykes et al., 1990). For example, 
collagen-like sequences on chromosome 11 have substantial 
length polymorphisms from variable numbers of a tandem repeat 
(Brooks et al., 1989) . There are reports of a region 
adjacent to the COL2Al gene which exhibits a high degree of 
length polymorphism due to the variation in the number of 
copies of a simple tandemly repeating dinucleotide sequence 
(Sykes et al., 1985; Stoker et al., 1985). The COL3Al gene 
contains a polymorphic block of dinucleotide repeats in one 
intron (Lee et al., 1991). Direct repeats have been shown to 
cause deletions in the helical coding portions of the COLlAl 
and COL1A2 collagen genes leading to the OI phenotype (Chu et 
al., 1985; Hawkins et al., 1991; Willing et al., 1988). A 
38bp insertion/deletion is a common polymorphism within an 
intron of the COL1A2 gene (Dalgleish et al., 1986). 
Recombination between direct Alu sequence repeats can cause 
clinical pathologies due to deletion of coding information 
(Stoppa-Lyonnet et al., 1990). 
The organization of the 18bp tandem repeat of NT899 is 
much like that of the direct repeats which cause 
polymorphisms seen in other collagen and non-collagen genes 
(Richards et al., 1992; Zuliani et al., 1990). Each 
repeating unit, AAG ACC AGC AGC CCA GAC, has an average of 
93. 3% identity to this sequence. Since there is high 
identity between the repeats of NT899, and they extend over 
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at least 617 base pairs, misalignment during DNA replication 
not only seems possible, but highly probable. Also, since 
most of the deletions seen in the OI patients are in the 
tandem repeat cluster, it strongly suggests that this 
repetitive organization facilitates the deletions. The 
absence of point mutations in the patient sequence eliminates 
them as the cause of the deletions. It is therefore likely 
that the direct repeat organization is the cause of the 
length variations seen at the Site 2 locus. 
Deletion Mechanism 
Direct repeats are frequently involved in causing 
deletions, including within collagen genes (Chu et al., 1985; 
Hawkins et al., 1991; Richards et al., 1992). The probable 
mechanism involved is slipped mispairing (Richards et al., 
1992), where during replication one direct repeat misaligns 
with another on the complementary strand causing looping out 
and subsequent excision of the intervening DNA (Ef stradiadis 
et al., 1980). Also, homologous chromosomes may misalign 
within the tandem cluster during meiosis, causing some of the 
DNA to loop out, creating deletions and frameshift mutations. 
Such repeat-mediated deletions appear to be occurring at 
Site 2. Since the deletions occur spontaneously (Doering et 
al, 1987) the slipped mispairing must be occurring during 
meiosis in the parent of an OI child or during early cell 
divisions in the embryo that will develop OI. The number of 
72 
tandem repeats may be a factor in the occurrence of slipped 
mispairing and deletions. Large clusters would facilitate 
more frequent slipped alignments. The number of tandem 18bp 
clusters found in NT899 is apparently large enough to make 
the region deletion prone. These tandem repeat clusters are 
thus unstable and can change each time they are transmitted 
from parent to child (Sutherland and Richards, 1994) . Also, 
deletions are often found that extend from tandemly repeated 
sequences into adjacent regions (Zuliani et al., 1990; 
Willing et al., 1988) . Thus, in some cases, as in one 
patient described in the present study, Site 2 deletions 
could be extending outside the 18bp tandem repeats. Slipped-
mispairing would not be the cause of this deletion. The 
specific location or extent of deletion within Site 2 may 
play a role in the expression of the OI phenotype. It is 
possible that individuals heterozygous for small deletions 
may be less affected, if at all, than individuals who are 
either heterozygous for larger deletions or homozygous for 
deletions at this locus. 
Relation to Other Repeat Disorders 
Fascioscapulo-humeral muscular dystrophy (FSHD) is 
associated with deletions in a tandemly repeated sequence 
(Winokur et al., 1994) . The cluster of 3. 2kb tandemly 
repeated unit is located on chromosome 4 and deletions in 
this region of at least 6kb show tight linkage to the 
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disease. The repeat cluster is actually adjacent to the FSHD 
gene, and how the deletions affect its expression is not yet 
known. Slipped-strand mispairing can also result in the 
duplication or amplification of repeated sequences. 
repeat clusters which expand in size are the 
Triplet 
sites of 
mutation in three heritable disorders, myotonic dystrophy, 
fragile X syndrome, and spinal and bulbar muscular atrophy. 
In these disorders, premutation or precursors of the full 
mutation alleles contain triplet-repeat sequences which, when 
amplified beyond a crucial threshold number, result in 
mutated alleles that cause the expression of the disease 
(Caskey et al., 1992). Parents with repeat cluster sizes 
below a specific threshold have mild or no disease, but give 
rise to significantly amplified repeats in progeny, who have 
the full disease phenotype (Caskey et al., 1992). The 
sequence amplifications that result in the disease phenotype 
in these patients is analogous to the Site 2 deletions 
associated with Type III OI. The parental deletions we have 
observed in OI families may be analogous to the premutation 
alleles. They could then give rise to the OI phenotype in 
offspring by further slipped-mispairing deletions. Further 
work will investigate if such premutation alleles exist in OI 
patients. 
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An Expressed Collagen-Like Gene 
There is strong genetic evidence that Site 2 is 
expressed, and that some of its deleted genotypes can lead to 
a detrimental phenotype against which selection operates 
Doering et al., 1993). The association of Site 2 deletions 
with OI Type III is one example of such a phenotype. 
Computerized analysis of the Site 2 sequence shows the 
presence of long open reading frames in the reverse 
translation frames (left to right in Figure 1) . Analysis of 
potential reading frames, codon preference, and GC bias 
suggests that the reverse translation frames contain coding 
information that could occur in a gene that is expressed 
(Cammarata, 1994) . The data are consistent with the presence 
of an expressed, collagen-like sequence being present on the 
reverse strand. 
Dot blot hybridizations of total RNA from normal diploid 
human fibroblasts to p4.6 sequences confirms that Site 2 is 
transcribed (Breslin et al., 1995) . Transcription 
experiments indicate that the gene is transcribed in the left 
to right direction on the restriction map as seen in Figure 
1 (Breslin et al., 1995). This is consistent with all the 
computer data that the Site 2 locus is an expressed collagen-
like gene. 
75 
Possible Function of the Site 2 Locus 
The level of GC richness (63%) seen in the NT899 
sequence is similar to that of other collagen and connective 
tissue (ECM) genes (Bernard et al., 1983) .Previous sequence 
comparisons of NT899 (Cammarata, 1994), have identified high 
similarity to a number of ECM components and transmembrane 
glycoproteins, which are important in directing the 
composition and structure of the extracellular matrix and 
effecting cellular interactions with the matrix (Alberts et 
al., 1994). This supports a function in which the putative 
protein encoded by the Site 2 locus could modulate the 
interaction of Type I collagen fibrils with the cell by 
acting as a communication bridge between them (Shaw and 
Olsen, 1991). This is possible via a signaling function 
which directs the secretion of ECM components or in a 
structural capacity, somehow connecting or associating the 
major fibril with other cell-secreted ECM components (Muller-
Glauser et al., 1986). 
The sequence pattern in the Site 2 gene is an 
interrupted collagen triplet sequence which contains a 
substitution for a glycine rather than a missing glycine. 
This pattern suggests that this molecule has the potential 
for flexibility while still maintaining a collagen-like a-
helical structure (Sandell et al., 1990). Cysteine residues 
allow inter- and intra-molecular crosslinking of the collagen 
polypeptide and are important in determining the structure of 
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the terminal globular domains of the Type IX molecules 
(Ninomiya et al., 1990). The abundance of these residues in 
p4. 6 suggest that the gene product has the capacity for 
farming other higher order structures in addition to a 
typical a-helix. 
Abnormal Type I collagen incorporated into fibrils has 
a drastic effect on tissue integrity, resulting in the OI 
phenotype (Prokop et al., 1989). Since the Site 2 collagen-
like gene is associated with the OI phenotype (Doering et 
al., 1987), it is likely that defects in its protein product, 
which result from deletion, will also contribute to the OI 
phenotype. Because the exact structure of the protein has 
not yet been identified, it is difficult to say specifically 
how these deletions affect its structure. 
If the Site 2 gene product does modulate Type I fibril 
interactions, then it has the potential to affect the 
strength and structural integrity of Type I collagen 
containing tissue. Thus, defects in p4.6 that disrupt this 
interactive capacity, could in turn effect the expression of 
the OI phenotype where a Type I collagen defect is or is not 
present. For example, there are many cases described where 
substitutions for glycine in similar positions of the same 
Type I collagen chain can produce drastic differences in OI 
severity between individuals (Cohn et al., 1991; Rose et al., 
1995; Forline et al., 1994) . It is possible that the 
additional presence of a Site 2 mutation could cause the more 
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severe condition, such as that seen in Type III OI. In some 
cases a single defect at the Site 2 locus could in itself 
result in the Type III OI phenotype. 
The deleted allele at Site 2 may not cause OI directly, 
but rather the defective product of the locus may interact 
with other mutant connective tissue components (such as Type 
I collagen) in producing the OI phenotype. There are many 
examples of asymptomatic individuals carrying the same Type 
I collagen defect as their family members that have OI (Cohn 
and Byers, 1991; Constantinou et al., 1989; Hollister et al., 
1988) . This suggests that the disease phenotype requires an 
interaction between Type I collagen and the products of other 
loci. Site 2 is a very good candidate for such a locus. 
Future work will determine if the size or location of Site 2 
deletions can be correlated with severity of symptoms in 
patients. 
Importance as a Diagnostic Tool 
Site 2 does not code for a true collagen molecule, but 
rather a protein with short collagen-like domains (Thiel and 
Reid, 1989). Whatever its product, the newly discovered 
locus is of importance, since our studies on OI patients and 
their families demonstrate that deletions at these sites are 
clearly associated with the disease and might serve as 
reliable diagnostic/genetic counseling markers for Type III 
OI. PCR screening of the repeat/deletion region could be a 
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simple, effective diagnostic indicator. This could be of 
real value for the many Type III cases not associated with 
Type I collagen defects, and could help in predicting 
severity of cases that do contain Type I defects. 
The PCR primers that flank the tandem repeat region in 
Site 2 amplify a 71lbp sequence, which is a much more 
sensitive means for detecting deletions than the Southern 
blot protocol (Doering et al., 1993), which used the entire 
4. 6kb Site 2 fragment. Being able to isolate the repeat 
region in a small fragment should detect short deletions and 
heterogeneity that previously went undetected. Deletions at 
the site would result in shorter than normal fragments being 
generated by the PCR. Simple comparison of the sizes of the 
DNA fragments generated from each sample would permit 
identification of individuals with a deletion, and what size 
the deletion is. Any sample that shows a Site 2 deletion by 
Southern blotting but does not show a deletion by PCR, would 
indicate that the deletion occurs outside the tandem repeat 
region. 
Future Studies 
We have already demonstrated the use of cycle 
sequencing to directly sequence PCR-amplified fragments in 
the Site 2 deletion region. It will also be important to 
examine the detailed sequences of deletions in some patients 
and their asymptomatic parents. Comparing the detailed 
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structures of the deletions in a patient and the asymptomatic 
parent could further elucidate the deletion mechanism and 
indicate whether the parent's deletion is an intermediate in 
the process of converting a normal allele to the patient's 
allele. Any correlation between the deletion size and 
severity of symptoms could eventually be a useful diagnostic 
tool. Also deletions in the normal population should be 
studied to see how their deletion sizes compare to those in 
patients and their parents. Comparing the normal deletions 
to those in asymptomatic parents would show if there is a 
premutation not found in the normal population, which could 
serve as a marker to identify individuals predisposed to 
having a child with the OI phenotype. 
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CHARACTERIZATION OF DELETION SITES 
IN A HUMAN COLLAGEN-LIKE LOCUS 
Osteogenesis imperfecta (OI) is a highly heterogeneous 
genetic disorder that affects bone and other connective 
tissues rich in Type I collagen. Previous studies have shown 
the existence of two previously-undescribed collagen-like 
loci, with sequence similarity to pro-a2(I) collagen. At 
these two sites deletions of heterogeneous size are found to 
be significantly more prevalent in OI type III patients than 
in the unaffected population. 
This study determined the molecular organization of the 
deletion site in one of the new collagen-like loci (Site 2). 
Sequencing reveals that the locus contains a region with 34 
copies of an 18bp tandemly-repetitive sequence. Using blots 
of restriction digested DNA from unaffected and OI patients, 
and PCR primers that flank the cluster of tandem repeats, I 
demonstrated that the deletions observed at this locus in OI 
patients usually occur within the tandem cluster. The 
molecular nature of the deletions was then determined by 
comparing the sequences of a short allele in an OI patient to 
the normal allele. The probable mechanism creating the 
deletions is slipped mispairing of misaligned repeats during 
DNA replication. 
